Select Publications

Conference Papers

Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2018, 'Study of CD44 variant 6 (CD44v6) in prostate cancer chemo-/radio resistance in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Chicago, IL, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Chicago, IL, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-1999

Ni J; Cozzi P; Beretov J; Deng J; Bucci J; Graham P; Li Y, 2017, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo/radio-resistance in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-2833

Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/beta-catenin signaling pathways in vitro', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, San Diego, CA, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), San Diego, CA, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-4005

Li Y; Liu WY, 2008, 'Backward probabilistic logic reasoning algorithm for decision problem with conditional event algebra on bayesian networks', in Proceedings of the 7th International Conference on Machine Learning and Cybernetics, ICMLC, pp. 1744 - 1749, http://dx.doi.org/10.1109/ICMLC.2008.4620687

You J; Fitzgerald A; Cozzi PJ; Zhao Z; Russell PJ; Walsh B; Willcox MD; Li Y, 2008, 'Identification of the potential biomakers for prostate cancer from tears and sera using proteomic methods', in The 13th Annual Proteomics Symposium Erskine Mantra Resort, 13th Annual Proteomics Symposium Erskine Mantra Resort, Lorne , VIC, presented at 13th Annual Proteomics Symposium Erskine Mantra Resort, Lorne , VIC, 08 February 2008 - 10 February 2008

Li Y; Wang JQ; Rizvi SM; Cozzi PJ; Madigan MC; Power C; Russell PJ; Allen BJ, 2006, 'Control of DU 145 and LNCaP-LN3 prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates', in Annals of Oncology, Oxford Univ Press, Oxford, England, pp. 47 - 47, presented at Symposium on targeted anticancer therapies, Amsterdam, 16 March 2006 - 18 March 2006, http://dx.doi.org/10.1093/annonc/mdl921

Li Y; Wang J; Zhang DY; Rizvi SMA; Lai K; Conway RM; Jager M; B illson FA; Allen BJ, 2004, 'In Vitro Targeting of NG2 antigen by 213Bi-9.2.27 radioimmunoconjugate induces cytotoxicity in human uveal melanoma cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at XVI international congress of eye research, 29 August 2004 - 03 September 2004

Li Y; Rizvi SMA; Wang J; Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJH; Allen BJ, 2004, 'Antigenic Expression of Human Metastatic Prostate Cancer Cell Lines and Primary Prostate Cancer Sections for In Vitro Multiple Targeted Alpha Therapy with 213Bi-conjugates.', in Antigenic Expression of Human Metastatic Prostate Cancer Cell Lines and Primary Prostate Cancer Sections for In Vitro Multiple Targeted Alpha Therapy with 213Bi-conjugates., 95th AACR annual meeting, presented at 95th AACR annual meeting, 27 March 2004 - 31 March 2004

Li Y; Syed SMA; Allen B, 2003, '213Bi-PAI2 conjugate selectively induced apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model', in 213Bi-PAI2 conjugate selectively induced apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model, 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003

Rizvi SMA; Li Y; Allen BJ, 2003, 'Evaluation of preclinical single and multiple dose toxicity and efficacy of 213Bi-labeled plasminogen activator inhibitor 2 for breast and prostate cancer.', in Evaluation of preclinical single and multiple dose toxicity and efficacy of 213Bi-labeled plasminogen activator inhibitor 2 for breast and prostate cancer., 17 September 2003 - 22 September 2003

Syed SMA; Li Y; Allen BJ, 2003, 'In vitro and in vivo targeted alpha therapy (TAT) of colorectal cancer using monoclonal antibodies c30 and 35A7', in In vitro and in vivo targeted alpha therapy (TAT) of colorectal cancer using monoclonal antibodies c30 and 35A7, 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003

Qu CF; Li Y; Rizvi SMA; Allen B, 2003, 'In vitro cytotoxicity of alpha conjugates for human pancreatic cancer cell lines', in In vitro cytotoxicity of alpha conjugates for human pancreatic cancer cell lines, 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003

Li Y; Cozzi PJ; Qu CF; Zhang D; Rizvi SMA; Raja C; Allen BJ, 2003, 'Targeted alpha therapy for human prostate cancer cell lines in vitro using -particle emitter (213Bi)-labeled Herceptin.', in Targeted alpha therapy for human prostate cancer cell lines in vitro using -particle emitter (213Bi)-labeled Herceptin., 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003


Back to profile page